Introducing the Life Sciences Verification Program

隆重推出生命科学验证计划 (LSVP)

Sep 17, 2026 2026年9月17日

Today, we are introducing the Life Sciences Verification Program (LSVP), which gives life science professionals access to our Mythos, Opus, and Sonnet models with a refined set of safeguards more permissive for biology-related work. We have already onboarded dozens of organizations through an early-access program, and are now opening applications to the broader life science community (apply here). The program is launching in beta, initially for teams and institutions. We will continue to improve the program and expand access to individual Pro and Max plans over time. 今天，我们正式推出“生命科学验证计划”（LSVP）。该计划旨在为生命科学专业人士提供对我们 Mythos、Opus 和 Sonnet 模型的访问权限，并配备了一套针对生物相关工作更为宽松的优化安全防护机制。我们此前已通过早期访问计划引入了数十家机构，现在正式向更广泛的生命科学界开放申请（点击此处申请）。该计划目前处于测试阶段，初期主要面向团队和机构。我们将持续改进该计划，并逐步扩大对个人 Pro 和 Max 计划用户的访问权限。

The LSVP is designed to enable life science professionals to use our models across a wide range of tasks that are currently blocked in our generally available Fable models, like drug discovery, research biology, clinical development, and manufacturing. It’s built for teams of all kinds—from academic labs to startups, pharma companies, and more. LSVP 旨在使生命科学专业人士能够利用我们的模型处理各种任务，这些任务在目前通用的 Fable 模型中是被拦截的，例如药物研发、生物学研究、临床开发和生产制造。该计划专为各类团队打造，涵盖学术实验室、初创企业、制药公司等。

Verification and access types

验证与访问类型

To qualify for these grants, each applicant goes through a verification process that includes a review of their research credentials, security standards, and ethical research oversight. Once verified, teams may apply for two types of LSVP grants, “Standard Use” or “High-risk Use,” depending on their access needs. These grants can be used through all our product surfaces, including Claude Science, Claude.ai, Claude Code and the API. 为了获得这些授权，每位申请者都必须经过验证流程，包括对其研究资质、安全标准和伦理研究监督的审查。一旦通过验证，团队可以根据其访问需求申请两种类型的 LSVP 授权：“标准用途”或“高风险用途”。这些授权可用于我们所有的产品界面，包括 Claude Science、Claude.ai、Claude Code 和 API。

Standard Use grants are suitable for most life science work, including the majority of biology research and development workflows. These grants can be extended to entire teams for diverse, daily workloads, and are renewed once a year. They give those teams access to our Mythos, Opus, and Sonnet models, with refined classifiers that are more permissive for science tasks than our generally available models. Standard Use grants apply to Mythos 5.1, Opus 5, and Sonnet 5 today, and to future models as they launch. They’re specifically designed to enable the full breadth of life science activities in areas spanning basic science, R&D, supply chain and manufacturing, clinical development, quality assurance, regulatory affairs, investing and diligence, and more. “标准用途”授权适用于大多数生命科学工作，包括绝大多数生物学研发流程。此类授权可扩展至整个团队以处理多样化的日常工作负载，并每年更新一次。它们使团队能够访问我们的 Mythos、Opus 和 Sonnet 模型，并配备了比通用模型对科学任务更具包容性的优化分类器。标准用途授权目前适用于 Mythos 5.1、Opus 5 和 Sonnet 5，并将适用于未来发布的新模型。它们专为支持广泛的生命科学活动而设计，涵盖基础科学、研发、供应链与制造、临床开发、质量保证、监管事务、投资与尽职调查等领域。

Although we expect Standard Use to cover the majority of access needs, some work carries a higher potential for misuse and therefore requires additional vetting. High-risk Use is an add-on grant for teams working in areas blocked under Standard Use. It removes all safeguards that block life sciences requests. This grant applies to a single research project as opposed to a full team, and must be renewed every six months. Typically, a single researcher with dual-use work would have access to one Standard Use grant for diverse, daily activities, and one or more High-risk Use grants which only apply to work on specific projects (for example, characterizing how one specific family of viral vectors is recognized by human immune pathways). 尽管我们预计“标准用途”能满足大多数访问需求，但某些工作存在更高的滥用风险，因此需要额外的审查。“高风险用途”是一项附加授权，适用于在“标准用途”下被拦截领域工作的团队。它移除了所有拦截生命科学请求的安全防护措施。此授权针对单个研究项目而非整个团队，且必须每六个月更新一次。通常情况下，一名从事双用途研究的研究人员将拥有一份用于日常多样化活动的“标准用途”授权，以及一份或多份仅适用于特定项目工作的“高风险用途”授权（例如，表征某种特定病毒载体家族如何被人类免疫通路识别）。

High-risk grants for Claude Opus 5 and Claude Sonnet 5 are available today. We are working with the US government to make high-risk grants more broadly available for Claude Mythos, but at the time of this launch they will remain limited to a small set of entities with additional vetting. Claude Opus 5 和 Claude Sonnet 5 的“高风险用途”授权现已开放。我们正与美国政府合作，以使 Claude Mythos 的高风险授权能够更广泛地提供，但在本次发布时，它们仍仅限于少数经过额外审查的实体。

All other safeguards, such as cyber classifiers, will remain in place under LSVP grants. 所有其他安全防护措施（如网络安全分类器）在 LSVP 授权下将保持不变。

Enabling trusted access through shared responsibility

通过共同责任实现可信访问

As we’ve shown in our recent threat report, there are increasingly sophisticated misuse attempts happening on our platform, including attempts that could support biological weapons development. In biology, where it’s often not possible to differentiate between a user doing valid work (e.g. research a viral pathogen to develop vaccines against it) and pursuing harm (e.g. trying to increase the transmissibility of a virus maliciously), the most concerning threat models are ones where valid access has been diverted or overtaken by an actor with bad intent. Indeed, insider threats and rogue-use have been major factors in significant biosafety incidents and scares. In developing the LSVP’s safeguards, we aimed to protect against three concerning threat models in particular: 正如我们在最近的威胁报告中所展示的那样，我们的平台上出现了日益复杂的滥用企图，包括可能支持生物武器开发的尝试。在生物学领域，往往难以区分用户是在进行正当工作（例如研究病毒病原体以开发疫苗）还是在追求恶意目的（例如试图恶意增加病毒的传播性）。最令人担忧的威胁模型是那些正当访问权限被恶意行为者挪用或接管的情况。事实上，内部威胁和违规使用已成为重大生物安全事件和恐慌的主要因素。在开发 LSVP 的安全防护措施时，我们特别旨在防范以下三种令人担忧的威胁模型：

• Access compromise: Malware or account takeover diverting access to a bad actor
• 访问受损： 恶意软件或账户接管导致访问权限被转移给恶意行为者
• Insider threats: Rogue or coerced employees intentionally taking malicious action or diverting their access to a bad actor
• 内部威胁： 违规或受胁迫的员工故意采取恶意行动，或将其访问权限转移给恶意行为者
• Agent misuse: Agents, especially working in swarms or over long-horizon tasks, taking unintended dangerous actions
• 智能体滥用： 智能体（尤其是以集群方式或执行长期任务时）采取了非预期的危险行动

In order to defend against these threats and in close collaboration with enterprise CISOs, we designed the new LSVP safeguards around the concept of shared responsibility by monitoring usage against the intended use-case for the model access. Because we vet the LSVP organizations for their life sciences credibility and oversight, we can empower them to specify for themselves what constitutes safe usage for teams or projects within their program. 为了抵御这些威胁，并与企业首席信息安全官（CISO）密切合作，我们围绕“共同责任”的概念设计了新的 LSVP 安全防护措施，即通过对照模型访问的预期用途来监控使用情况。由于我们对 LSVP 组织在生命科学领域的信誉和监督能力进行了审查，我们能够授权他们自行定义其计划内团队或项目的安全使用规范。

Each entity’s access is tied to the use cases it has specified in its grant applications, and we continuously monitor LSVP traffic to identify usage or patterns that are outside the stated safe scope. Should unauthorized activity occur, we can flag these cases to organization admins to take action within pre-agreed timeframes for triaging and remediating incidents. The use cases should include high-level descriptions of the intended work, like one would share in a job listing, and not include any sensitive information or IP. 每个实体的访问权限都与其在授权申请中指定的用例挂钩，我们会持续监控 LSVP 流量，以识别超出既定安全范围的使用行为或模式。如果发生未经授权的活动，我们会向组织管理员标记这些案例，以便在预先商定的时间内采取行动，对事件进行分类和补救。用例应包含对预期工作的高层描述（类似于职位描述中的内容），且不得包含任何敏感信息或知识产权。

How monitoring works in LSVP

LSVP 中的监控机制

Serious misuse is often spread across many requests and sessions to look disconnected and evade detection. In the LSVP, we are shifting safeguards from real-time blocking, where we reject potentially harmful access at the time of each request, to offline monitoring, which allows us to more clearly identify potential misuse across patterns of behavior. Shifting enforcement from real-time blocking to offline monitoring allows legitimate work to proceed with fewer interruptions, but it requires us to reta… 严重的滥用行为通常分散在多次请求和会话中，以伪装成互不关联的活动来逃避检测。在 LSVP 中，我们将安全防护机制从“实时拦截”（即在每次请求时拒绝潜在的有害访问）转向“离线监控”，这使我们能够更清晰地识别跨行为模式的潜在滥用。将执行方式从实时拦截转向离线监控，可以让合法工作在更少干扰的情况下进行，但这要求我们……